Fungal genetics, genomics, and secondary metabolites in pharmaceutical sciences

Planta Medica

Volumn 73, Issue 2, 2007, Pages 103-115

  Misiek, Mathias ^a   Hoffmeister, Dirk ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Fungi; Gene cluster; Genomics; Natural products

Indexed keywords

ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; ASTERRIQUINONE DERIVATIVE; CASPOFUNGIN; CLEROCIDIN; ECHINOCANDIN; FUMAGILLIN; GYRASE INHIBITOR; IROFULVENE; MICAFUNGIN; NA 255; NATURAL PRODUCT; PLECTASIN; POLYPEPTIDE ANTIBIOTIC AGENT; SESQUITERPENE; SORDARIN; TIAMULIN; TRYPROSTATIN; UNCLASSIFIED DRUG;

BIOSYNTHESIS; DRUG ACTIVITY; DRUG RESEARCH; FUNGAL GENETICS; GENOMICS; NONHUMAN; REVIEW; VIRUS REPLICATION;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; FUNGI; GENES, FUNGAL; GENOME, FUNGAL; GENOMICS; MULTIGENE FAMILY;

FUNGI;

EID: 34250379220     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-967104     Document Type: Review

References (111)

1. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005; 4: 206-20.
2. Turner WB, Aldridge DC. Fungal metabolites II. London and New York: Academic Press; 1983.
3. Cole RJ, Schweickert MA. Handbook of secondary fungal metabolites. Vol. 1-3. London: Academic Press; 2003.
4. Wasson RG, Hofmann A, Ruck CAP. The road to Eleusis, 2nd edition. Los Angeles: Hermes Press; 1998.
5. Hardman JG, Limbird LE. The pharmacological basis of therapeutics, 10th edition. Goodman and Gilman's London: McGraw-Hill; 2002.
6. Demain AL, Elander RP. The beta-lactam antibiotics: past, present, and future. 1999; 75: 5-19.
7. Schardl CL, Panaccione DG, Tudzynski P. Ergot alkaloids - biology and molecular biology. Alkaloids 2006; 3: 45-86.
8. Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2003; 2: 517-26.
9. Berth-Jones J. The use of ciclosporin in psoriasis. J Dermatol Treat 2005; 16: 258-77.
10. Rogers TR. Antifungal drug resistance: limited data, dramatic impact? Int J Antimicrob Agents 2006; 27S: S7-11.
11. Vicente MF, Basilio A, Cabello A, Peláez F. Microbial natural products as a source of antifungals. Clin Microbiol Infect 2003; 9: 15-32.
12. Odds FC, Brown AJP, Gow NAR. Antifungal agents: mechanisms of action. Trends Microbiol 2003; 11: 272-9.
13. Nyfelder R, Keller SW. Metabolites of microorganisms, 143: echino-candin B, a novel polypeptide-antibiotic from Aspergillus nidulans var. echinulatus-isolation and structural components. Helv Chim Acta 1974; 57: 2459-77.
14. Letscher-Bru V, Herbrecht R. Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 2003; 51: 513-21.
15. Raasch RH. Anidulafungin: review of a new echinocandin antifungal agent. Expert Rev Anti Infect Ther 2004; 2: 499-508.
16. Vasquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis 2006; 43: 215-22.
17. Zaas AK, Steinbach WJ. Micafungin: the US perspective. Expert Rev Anti Infect Ther 2005; 3: 183-90.
18. de Wet NT, Bester AJ, Viljoen JJ, Filho F, Suleiman JM, Ticona E et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophagial candidasis. Aliment Pharmacol Ther 2005; 21: 899-907.
19. Krause DS, Simjee AE, van Rensburg C, Viljoen J, Walsh TJ, Goldstein BP et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidasis. Clin Infect Dis 2004; 39: 770-5.
20. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double blind, multicenter study of caspofungin versus amphotericin B in treatment of oropharyngeal and esophageal candidasis. Antimicrob Agents Chemother 2002; 46: 451-7.
21. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-51.
22. Zaas AK, Alexander BD. Echinocandins: role in antifungal therapy. Expert Opin Pharmacother 2005; 6: 1657-68.
23. Turner MS, Drew RH, Perfect JR. Emerging echinocandins for treatment of invasive fungal infections. Expert Opin Emerg Drugs 2006; 11: 231-50.
24. Moore CB, Oakley KL, Denning DW. In vitro activity of a new echino-candin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin Microbiol Infect 2001; 7: 11-6.
25. Kurtz MB, Heath IB, Marrinan J, Dreikorn S, Onishi J, Douglas C. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob Agents Chemother 1994; 38: 1480-9.
26. Kurtz MB, Abruzzo G, Flattery A, Bartizal K, Marrinan J, Li W et al. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect Immun 1996; 64: 3244-51.
27. Odds FC. Sordarin antifungal agents. Expert Opin Ther Patents 2001; 11: 283-94.
28. Dominguez JM, Martin JJ. Sordarins: inhibitors of fungal elongation factor-2. In: An Z, editor. Handbook of industrial mycology New York: Marcel Dekker; 2004: 335-53.
29. Hauser D, Sigg HP. Isolierung und Abbau von Sordarin. Helv Chim Acta 1971; 54: 1178-90.
30. Dominguez JM, Kelly VA, Kinsman OS, Marriott MS, Gómez de las Heras F, Martin JJ. Sordarins: a new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts. Antimicrob Agents Chemother 1998; 42: 2274-8.
31. Herreros E, Almela MJ, Lozano S, Gómez de las Heras F, Gargallo-Viola D. Antifungal activities and cytotoxicity studies of six new azasordarins. Antimicrob Agents Chemother 2001; 45: 3132-9.
32. Basilio A, Justice M, Harris G, Bills G, Collado J, de la Cruz M et al. The discovery of moriniafungin, a novel sordarin derivative produced by Morinia pestalozzioides. Bioorg Med Chem 2006; 14: 560-6.
33. Dominguez JM, Martin JJ. Identification of Elongation Factor 2 as the essential protein targeted by Sordarins in Candida albicans. Antimicrob Agents Chemother 1998; 42: 2279-83.
34. Jimenez E, Martinez A, Aliouat EM, Caballero J, Dei-Cas E, Gargallo-Viola D. Therapeutic efficacies of GW471552 and GW471558, two new azasordarin derivatives, against pneumocystosis in two immunosuppressed-rat models. Antimicrob Agents Chemother 2002; 46: 2648-50.
35. Kamai Y, Kakuta M, Shibayama T, Fukuoka T, Kuwahara S. Antifungal activities of R-135853, a sordarin derivative, in experimental candidiasis in mice. Antimicrob Agents Chemother 2005; 49: 52-6.
36. Hunt E. Pleuromutilin Antibiotics Drugs. Future 2000; 25: 1163-8.
37. Schlünzen F, Pyetan E, Fucini P, Yonath A, Harms JM. Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol Microbiol 2004; 54: 1287-94.
38. Long KS, Hansen LH, Jakobsen L, Vester B. Interaction of pleuromutilin derivatives with the ribosomal peptidyl transferase center. Antimicrob Agents Chemother 2006; 50: 1458-62.
39. Jones RN, Fritsche TR, Sader HS, Ross JE. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrob Agents Chemother 2006; 50: 2583-6.
40. Pankuch GA, Lin G, Hoellman DB, Good CE, Jacobs MR, Appelbaum PC. Activity of retapamulin against Streptococcus pyogenes and Staphylo coccus aureus evaluated by agar dilution, microdilution, E-test, and disk diffusion methodologies. Antimicrob Agents Chemother 2006; 50: 1727-30.
41. Free A, Roth E, Dalessandro M, Hiram J, Scangarella N, Shawar R et al. Retapamulin ointment twice daily for 5 days vs oral cephalexin twice daily for 10 days for empiric treatment of secondarily infected traumatic lesions of the skin. Skinmed 2006; 5: 224-32.
42. Parish LC, Jorizzo JL, Breton JJ, Hirman JW, Scangarella NE, Shawar RM et al. (On behalf of the SB275833/032 study team.) Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: Results of a randomized controlled trial. J Am Acad Dermatol 2006; 55: 1006-16.
43. Cullough JE, Muller MT, Howells AJ, Maxwell A, O'Sullivan J, Summerill RS et al. Clerocidin, a terpenoid antibiotic, inhibits bacterial DNA gyrase. J Antibiot 1993; 46: 526-30.
44. Richter SN, Leo E, Giaretta G, Gatto B, Fischer LM, Palumbo M. Clerocidin interacts with the cleavage complex of Streptococcus pneumoniae topoisomerase IV to induce selective irreversible DNA damage. Nucleic Acids Res 2006; 34: 1982-91.
45. Mygind PH, Fischer RL, Schnorr KM, Mogens TH, Sönksen CP, Ludvigsen S et al. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 2005; 437: 975-80.
46. Park Y, Hahm KS. Antimicrobial peptides (AMPs): peptide structure and mode of action. J Biochem Mol Biol 2005; 38: 507-16.
47. Raventós D, Taboureau O, Mygind PH, Nielsen JD, Sonksen CP, Kristensen HH. Improving on nature's defenses: optimization & high throughput screening of antimicrobial peptides. Comb Chem High Throughput Screen 2005; 8: 219-33.
48. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005; 4: 236-48.
49. Lataillade M, Kozal MJ. The hunt for HIV-1 integrase inhibitors. AIDS Patient Care STDS 2006; 20: 489-501.
50. Herath KB, Jayasuriya H, Bills GF, Polishook JD, Dombrowski AW, Guan Z et al. Isolation, structure, absolute stereochemistry, and HIV-1 integrase inhibitory activity of integrasone, a novel fungal polyketide. J Nat Prod 2004; 67: 872-4.
51. Singh SB, Pelaez F, Hazuda DJ, Lingham RB. Discovery of natural product inhibitors of HIV-1 integrase at Merck. Drugs Future 2005; 30: 277-99.
52. Marchand C, Johnson A, Karki RG, Pais GCG, Zhang X, Cowansage K et al. Metal-dependent inhibition of HIV-1 integrase by β-diketo acids and resistance of the soluble double-mutant (F185K/C280S). Mol Pharmacol 2003; 64: 600-9.
53. Sakamoto H, Okamoto K, Aoki M, Kato H, Katsume A, Ohta A. Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat Chem Biol 2005; 1: 333-7.
54. McMorris TC, Elayadi AN, Yu J, Hu Y, Kelner MJ. Metabolism of antitumor hydroxymethylacylfulvene by rat liver cytosol. Drug Metab Dispos 1999; 27: 983-5.
55. McMorris TC, Elayadi AN, Yu J, Kelner MJ. Metabolism of antitumor acylfulvene by rat liver cytosol. Biochem Pharmacol 1999; 57: 83-8.
56. McMorris TC, Yu J, Lira R, Dawe R, MacDonald JR, Waters SJ et al. Structure-activity studies of antitumor agent irofulvene (hydroxymethylacylfulvene) and analogues. J Org Chem 2001; 66: 6158-63.
57. Gregerson LN, McMorris TC, Siegel JS, Baldridge KK. Ab initio structure/reactivity investigations of illudin-based antitumor agents: a model for reaction in vivo. Helv Chim Acta 2003; 86: 4133-51.
58. Kelner MJ, McMorris TC, Taetle R. Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxity. J Natl Cancer Inst 1990; 82: 1562-5.
59. Seiden MV, Gordon AN, Bodurka DC, Matulonis UA, Penson RT, Reed E et al. A phase II study of irofulvene in women with recurrent and heavily pretreated ovarian cancer. Gynecol Oncol 2006; 101: 55-61.
60. Senzer N, Arsenau J, Richards D, Berman B, MacDonald JR, Smith S. Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial. Am J Clin Oncol 2005; 28: 36-41.
61. Bomgaars LR, Megason GC, Pullen J, Langevin AM, Weitman SD, Hershon L et al. Phase I trial of irofulven (MG 114) in pediatric patients with solid tumors. Pediatr Blood Cancer 2006; 47: 163-8.
62. Serova M, Calvo F, Lokiec F, Koeppel F, Poindessous V, Larsen AK et al. Characterizations of irofulven cytotoxity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells. Cancer Chemother Pharmacol 2006; 57: 491-9.
63. Van Laar ES, Roth S, Weitman S, MacDonald JR, Waters SJ. Activity of irofulven against human pancreatic carcinoma cell lines in vitro and in vivo. Anticancer Res 2004; 24: 59-65.
64. Zhang Y, Yeh JR, Mara A, Ju R, Hines JF, Cirone P et al. A chemical and genetic approach to the mode of action of fumagillin. Chem Biol 2006; 13: 1001-9.
65. Lu J, Chong CR, Hu X, Liu JO. Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo. J Med Chem 2006; 49: 5645-8.
66. Bernier SG, Lazarus DD, Clark E, Doyle B, Labenski MT, Thompson CD et al. A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proc Natl Acad Sci USA 2004; 101: 0768-73.
67. Didier PJ, Phillips JN, Kuebler DJ, Nasr M, Brindley PJ, Stovall ME et al. Antimicrosporidial activities of fumagillin, TNP-470, ovalicin, and ovalicin derivatives in vitro and in vivo. Antimicrob Agents Chemother 2006; 50: 2146-55.
68. Usui T, Kondoh M, Cui CB, Mayumi T, Osada H. Tryprostatin A, a specific and novel inhibitor of microtubule assembly. Biochem J 1998; 333: 543-8.
69. Zhao S, Smith KS, Deveau AM, Dieckhaus CM, Johnson MA, Macdonald TL et al. Biological activity of the tryprostatins and their diastereomers on human carcinoma cell lines. J Med Chem 2002; 45: 1559-62.
70. Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. Fumitre-morgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 2000; 60 : 7-50.
71. Yamamoto Y, Nishimura KI, Kiriyama N. Studies on the metabolic products of Aspergillus terreus. I. Metabolites of the strain IFO 6123. Chem Pharm Bull 1976; 24: 853-9.
72. Yamamoto Y, Kiriyama N, Shimizu S, Koshimura S. Antitumor activity of asterriquinone, a metabolic product from Aspergillus terreus. Gann 1976; 67: 623-4.
73. Kaji A, Iwata T, Kiriyama N, Nomura M, Miyamoto KI. Studies on the cytotoxicity of asterriquinone derivatives. J Antibiot 1998; 51: 235-8.
74. Fredenhagen A, Petersen F, Tintelot-Blomley M, Rösel J, Mett H, Hug P. Semicochliodinol A and B: inhibitors of HIV-1 protease and EGF-R protein tyrosine kinase related to asterriquinones produced by the fungus Chrysosporium merdarium. J Antibiot 1997; 50: 395-401.
75. Zhang B, Salituro G, Szalkowski D, Li Z, Zhang Y, Royo I et al. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science 1999; 284: 974-7.
76. Velliquette RA, Friedman JE, Shao J, Zhang B, Ernsberger P. Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferatoraActivated receptor γ-agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X. J Pharmacol Exp Ther 2005; 314: 422-30.
77. Keller NP, Hohn TM. Metabolic pathway gene clusters in filamentous fungi. Fungal Genet Biol 1997; 21: 17-29.
78. Hoffmeister D, Keller NP. Natural products of filamentous fungi: enzymes, genes, and their regulation. Nat Prod Rep; 2007, in press.
79. Bok JW, Keller NP. LaeA, a regulator of secondary metabolism in Aspergillus spp. Euk Cell 2004; 3: 527-35.
80. Rosewich UL, Kistler HC. Role of horizontal gene transfer in the evolution of fungi. Annu Rev Phytopathol 2000; 38: 325-63.
81. Walton JD. Horizontal gene transfer and the evolution of secondary metabolite gene clusters in fungi: an hypothesis. Fungal Genet Biol 2000; 30: 167-71.
82. Hill AM. The biosynthesis, molecular genetics and enzymology of the polyketide-derived metabolites. Nat Prod Rep 2006; 23: 256-320.
83. Walsh CT. Polyketide and nonribosomal peptide antibiotics: modularity and versatility. Science 2004; 303: 1805-10.
84. Schwarzer D, Finking R, Marahiel MA. Nonribosomal peptides: from genes to products. Nat Prod Rep 2003; 20: 275-87.
85. Schümann J, Hertweck C. Advances in cloning, functional analysis and heterologous expression of fungal polyketide synthase genes. J Biotechnol 2006; 124: 690-703.
86. Martin JF. New aspects of genes and enzymes for beta-lactam antibiotic biosynthesis. Appl Microbiol Biotechnol 1998; 50: 1-15.
87. Elander RP. Industrial production of beta-lactam antibiotics. Appl Microbiol Biotechnol 2003; 61: 385-92.
88. Aharonowitz Y, Cohen G, Martin JF. Penicillin and cephalosporin biosynthetic genes: structure, organization, regulation, and evolution. Annu Rev Microbiol 1992; 46: 461-95.
89. Lamas-Maceiras M, Vaca I, Rodriguez E, Casqueiro J, Martin JF. Amplification and disruption of the phenylacetyl-CoA ligase gene of Penicillium chrysogenum encoding an aryl-capping enzyme that supplies phenylacetic acid to the isopenicillin N-acyltransferase. Biochem J 2006; 395: 147-55.
90. Fierro F, Garcia-Estrada C, Castillo NI, Rodriguez R, Velasco-Conde T, Martin JF. Transcriptional and bioinformatic analysis of the 56.8 kb DNA region amplified in tandem repeats containing the penicillin gene cluster in Penicillium chrysogenum. Fungal Genet Biol 2006; 43: 618-29.
91. Burzlaff NI, Rutledge PJ, Clifton IJ, Hensgens CM, Pickford M, Adlington RM et al. The reaction cycle of isopenicillin-N-synthase observed by X-ray diffraction. Nature 1999; 401: 721-4.
92. Valegard K, van Scheltinga AC, Lloyd MD, Hara T, Ramaswamy S, Perrakis A et al. Structure of a cephalosporin synthase. Nature 1998; 394: 805-9.
93. Gröger D, Mothes KV, Simon H, Floss HG, Weygand F. On the incorporation of mevalonic acid in the ergoline system of clavine alkaloids. Z Naturforsch 1960; 15B: 141-3.
94. Gröger D, Floss HG. Biochemistry of ergot alkaloids - achievements and challenges. In: Cordell GA, editor. The Alkaloids. San Diego: Academic Press; 1998: 171-218.
95. Haarmann T, Machado C, Lubbe Y, Correia T, Schardl CL, Panaccione DG et al. The ergot alkaloid gene cluster in Claviceps purpurea: extension of the cluster sequence and intra species evolution. Phytochemistry 2005; 66: 1312-20.
96. Panaccione DG. Origins and significance of ergot alkaloid diversity in fungi. FEMS Microbiol Lett 2005; 251: 9-17.
97. Lawen A, Zocher R. Cyclosporin synthetase. The most complex peptide synthesizing multienzyme polypeptide so far described. J Biol Chem 1990; 265: 1355-60.
98. Dittmann J, Lawen A, Zocher R, Kleinkauf H. Isolation and partial characterization of cyclosporin synthetase from a cyclosporin non-producing mutant of Beauveria nivea. Biol Chem Hoppe-Seyler 1990; 371: 829-34.
99. Weber G, Schörgendorfer K, Schneider-Scherzer E, Leitner E. The peptide synthetase catalyzing cyclosporine production in Tolypocladium niveum is encoded by a giant 45.8-kilobase open reading frame. Curr Genet 1994; 26: 120-5.
100. Kennedy J, Auclair K, Kendrew SG, Park C, Vederas JC, Hutchinson CR. Modulation of polyketide synthase activity by accessory proteins during lovastatin biosynthesis. Science 1999; 284: 368-72.
101. Abe Y, Suzuki T, Ono C, Iwamoto K, Hosobuchi M, Yoshikawa H. Molecular cloning and characterization of an ML-236B (compactin) biosynthetic gene cluster in Penicillium citrinum. Mol Gen Genet 2002; 267: 636-46.
102. Galagan JE, Calvo SE, Cuomo C, Ma LJ, Wortman JR, Batzoglou S et al. Sequencing of Aspergillus nidulans and comparative analysis with A. fumigatus and A. oryzae. Nature 2005; 438: 1105-15.
103. Nierman WC, Pain A, Anderson MJ, Wortman JR, Kim HS, Arroyo J et al. Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature 2005; 438: 1151-6.
104. Machida M, Asai K, Sano M, Tanaka T, Kumagai T, Terai G et al. Genome sequencing and analysis of Aspergillus oryzae. Nature 2005; 438: 1157-61.
105. Bok JW, Hoffmeister D, Maggio-Hall LA, Murillo R, Glasner JD, Keller NP. Genomic mining for Aspergillus natural products. Chem Biol 2006; 13: 31-7.
106. Scherlach K, Hertweck C. Discovery of aspoquinolones A-D, prenylated quinoline-2-one alkaloids from Aspergillus nidulans, motivated by genome mining. Org Biomol Chem 2006; 45: 7835-8.
107. Lee BN, Kroken S, Chou DY, Robbertse B, Yoder OC, Turgeon BG. Functional analysis of all nonribosomal peptide synthetases in Cochliobolus heterostrophus reveals a factor, NPS6, involved in virulence and resistance to oxidative stress. Euk Cell 2005; 4: 545-55.
108. Jones T, Federspiel NA, Chibana H, Dungan J, Kalman S, Magee BB et al. The diploid genome sequence of Candida albicans. Proc Natl Acad Sci USA 2004; 101: 7329-34.
109. Braun BR, van Het Hoog M, d'Enfert C, Martchenko M, Dungan J, Kuo A et al. A human-curated annotation of the Candida albicans genome. PLoS Genet 2005; 1: E1.
110. De Backer MD, Nelissen B, Logghe M, Viaene J, Loonen I, Vandoninck S et al. An antisense-based functional genomics approach for identification of genes critical for growth of Candida albicans. Nat Biotechnol 2001; 19: 212-3.
111. De Backer MD, Van Dijck P. Progress in functional genomics approaches to antifungal drug target discovery. Trends Microbiol 2003; 11: 470-8.